Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 and QIV Co-administration Study
NCT05734040Phase 2Completed
- Sponsor
- Osivax
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OVX836 in influenza, sponsored by Osivax. Started May 2023; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05734040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734040.